T here are a number of pathophysiologic processes that may result in the multiple organ dysfunction syndrome (MODS) in children. To begin, certain underlying diagnoses including, but not limited to cancer, congenital heart disease, inborn errors of metabolism, and rheumatologic diseases have all been associated with a predisposition to the syndrome. Similarly, acute conditions such as sepsis, acute respiratory distress syndrome (ARDS), acute kidney injury, liver failure, and pancreatitis have also been associated with the process. Additionally, pathophysiologic processes such as hypoxia (of any source) can be potent triggers of MODS as observed following cardiopulmonary arrest. Furthermore, acute insults such as multiple trauma and thermal injuries have also been found to result in MODS. Conversely, numerous treatments and therapeutic regimens such as antineoplastic therapies, blood transfusions, and hematopoietic and solid organ transplantation have all been reported to elicit MODS. Given the breadth of these various topics, any attempt to provide a comprehensive review of the many etiologies of MODS would be grossly insufficient, and thus, that is not the intent of this article. Conditions commonly associated with MODS such as inborn errors of metabolism, brain injury and neurologic insult, and rheumatologic disorders are not addressed in this or its accompanying article. The available literature contains a host of publications and reviews addressing the individual topics and their association with MODS. The purpose of this article is simply to encourage investigators to consider the topic from the perspective of other disciplines to hopefully identify areas of commonality, enhance the body of knowledge of respective disciplines, and identify opportunities for future study ( Table 1) .
Sepsis
Sepsis is a common cause of MODS. It is defined in its simplest form as a systemic inflammatory response syndrome (SIRS) caused by an infection (1) . Although sepsis has most recently been redefined for adults (2) , those definitions have not been applied to children to date. Thus, this discussion will continue to use the definitions initially proposed at the International Pediatric Sepsis Consensus Conference held in 2005. Based on those proceedings, the proposed diagnostic criteria of SIRS include the presence of alterations in at least two of four criteria including temperature, heart rate, respiratory rate, and/or WBC count (1) . This set of diagnostic criteria for SIRS has subsequently been found to demonstrate excellent interobserver reliability (3) . In addition to SIRS, several other definitions were proposed at the International Pediatric Sepsis Consensus Conference. For example, "infection" was defined as a suspected or proven infection (by positive culture, tissue stain, or polymerase chain reaction test) caused by any pathogen or a clinical syndrome associated with a high probability of infection (1) . Evidence of infection includes positive findings on clinical examination, imaging, or laboratory tests (e.g., WBCs in a normally sterile body fluid, perforated viscus, chest radiograph consistent with pneumonia, petechial or purpuric rash, or purpura fulminans). "Severe sepsis" was defined as sepsis plus cardiovascular organ dysfunction or ARDS or two or more other organ dysfunctions. "Septic shock" was defined as sepsis and cardiovascular organ dysfunction as defined in the MODS diagnostic criteria. Sepsis may be caused by all forms of microbes including bacteria, viruses, protozoans, and fungi. The most frequent causes of community-and hospital-acquired infection in the PICU are in decreasing order: respiratory infections (37%), bacteremia (25%), urinary tract infections, intra-abdominal infections, softtissue infections, CNS infections, endocarditis, fasciitis, etc (4) .
Of the many etiologies of MODS, the association between MODS and sepsis is perhaps the most studied in children, and it is important to understand that relationship (Fig. 1) .
Although not all cases of MODS are caused by an infection, all severe infections can progress to MODS. In addition, septic patients must receive antibiotics as soon as possible; even a delay as short as 30 minutes increases the risk of MODS and death (5) . The relationship between MODS and sepsis is exemplified by the cumulative effect on mortality of MODS severity and the septic state. Leclerc et al (6) analyzed the cumulative influence of organ dysfunctions and the presence A better understanding of the influence that pulmonary and immune system maturation have on the pathophysiology of ARDS needs to be established with an attempt to explain the differences between children and adults in terms of outcomes and the occurrence of MODS associated with ARDS.
The impact of age on the occurrence of MODS following cardiac surgery and cardiopulmonary bypass needs to be better established. Moreover, similarities and differences between MODS in the setting of cardiac repair and other etiologies such as sepsis and trauma need to be elucidated; such study may improve outcomes in each of these settings.
Established triggers of MODS with well-defined timelines such as cardiopulmonary bypass and antineoplastic therapy need to be used as models for studying MODS. The conditions associated with these interventions such as congenital heart disease and cancer represent opportunities for long-term follow-up of MODS and the impact of multiple insults.
The role of anticytokine therapy in conditions associated with MODS needs to be determined. However, to do so, mediating biomarkers must first be identified that can be assessed in a clinically relevant time frame as has been accomplished for the cytokine release syndrome.
Mortality among pediatric hematopoietic cell patients remains unacceptably high, and there is a clear association of mortality with MODS in this patient population. In order to advance this field, early predictors of patients at risk need to be identified. The development of novel strategies that reduce transplant-related toxicity in combination with the discovery of biomarkers that may predict the development, severity, and response to therapy of these complications must be further established.
of sepsis on mortality using the PEdiatric Logistic Organ Dysfunction (PELOD) score among 593 consecutive admissions of critically ill children to one of three PICUs. In that study, 514 patients had SIRS; 269 of whom had two or more organ dysfunctions (severe sepsis). The hazard ratio (HR) of death associated with SIRS or sepsis was similar (9.039) and was significantly higher than the risk of death in patients without SIRS or sepsis (p = 0.031). The SIRS/sepsis patients were grouped together for further analysis. Thus, the description of the severity of illness is improved in critically ill children by consideration of both the severity of MODS and the status of the septic condition. The predictive value of this combined evaluation is better than the predictive value of MODS or septic state alone. Although these definitions of SIRS and sepsis are imperfect and likely to be soon revised for children, they add useful information. aRDS ARDS is a syndrome of inflammation and increased permeability in the lungs associated with a pattern of clinical, radiologic, and physiologic abnormalities that cannot be explained by, but may coexist with, left atrial or pulmonary capillary hypertension (7) . Although there are similarities in the pathophysiology of ARDS between adults and children, pediatricspecific practice patterns, comorbidities, and differences in outcome prompted the recent development of a pediatricspecific operational definition for ARDS by the Pediatric Acute Lung Injury Consensus Conference Group (Fig. 2) (8) . In pediatrics, the occurrence and mortality of ARDS are lower than published rates for adults. Specifically, pediatric ARDS (PARDS) occurrence rates range from 2 to 12.8 per 100,000 person-years, whereas mortality rates span from 18 to 27% (9) . However, despite these documented differences with adults, most of our knowledge related to PARDS is derived from studies in adult patients or in mature animals with very few studies performed in children or in young animal models (10) . This void in pediatric-specific inquiry presents a problem because pulmonary and immune system maturation may impact the pathophysiology of PARDS and may be significantly different then what has been described in adult ARDS. Differences in the innate immunologic response to critical illness may account for the variation in the rate of multiple organ failure between critically ill children and adults (11) . These fundamental differences may impact the diagnosis, severity, and optimal therapeutic approach in the management of PARDS.
PARDS can be associated with MODS either as the precipitant of the other organ dysfunctions or as an additional organ dysfunction incited by another trigger. Either way, MODS at the onset of PARDS is an important independent clinical risk factor for mortality in children (12) (13) (14) . In addition, as mortality from PARDS continues to decrease, rates of new or progressive organ system dysfunction and organ failure-free days have been recommended as alternative endpoints for clinical trials of PARDS (15) .
Congenital Heart Disease/Cardiopulmonary bypass
In the United States alone, there are approximately 400,000 cardiac surgical operations performed employing cardiopulmonary bypasses (CPB) each year, of which 10,000 are performed on children. In nearly all cases, cardiac surgical operations performed on children employing CPB induce ischemia with subsequent reperfusion injury resulting from the reinitiation of flow following circulatory arrest and removal of the crossclamp. These pathophysiologic processes not only cause injury themselves through myocardial necrosis, renal injury, and neurologic injury but also activate a systemic inflammatory response characterized by multisystem organ dysfunction and failure. The sum total of these pathologic processes is postoperative morbidity and mortality that is significantly worse in the infant than compared with that in the adult (16) . However, unlike other triggers associated with whole-body inflammatory reactions such as trauma or sepsis, cardiac surgical teams have the advantage of knowing when the trigger will occur (i.e., during CPB) and hence have an opportunity for preemptive intervention in an effort to attenuate or minimize the response.
The vast majority of patients undergoing congenital cardiac repair with bypass have some degree of MODS. Published reports indicate that this rate varies between 4% and 80% (17) . If cardiac dysfunction is included, virtually all patients have MODS. However, the outcomes in this population are excellent. This raises the possibility that MODS following this type of injury is fundamentally different than that in other critical disease processes. It is possible that this population requires separate definitions of MODS. 
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The fact that the injury in this population is initiated through the necessity of performing a cardiac repair provides an opportunity to investigate the mechanisms involved. There are very few situations in which the timing of the injury can be controlled, and thus, it is incumbent upon investigators to leverage this factor. Certainly, there are challenges to such investigations including diverse baseline cardiac diseases and physiologic states, as well as unique bypass strategies, operative approaches, and anesthetic management. However, this represents an opportunity for not only study, but also preemptive intervention. Current interventional approaches involve modulation of the inflammatory response including steroids and nitric oxide (16, 18, 19) . In addition, such study also allows investigation into the roles of the multiple variables such as preoperative state and age. It is clear that cardiac injury and recovery from inflammation are affected by the age of the patient (20) . This may be particularly true in the cardiac surgical patient. Within this particular population, we have the opportunity to examine the response to injury and progression to MODS across the spectrum of age from the neonate to the 90-year-old patient receiving a valve replacement.
Additionally, there exists the potential to examine a single population, or even a single patient, across multiple surgical exposures and insults because of the requirement for several staged surgical palliative procedures throughout a lifetime. In addition, since complex congenital cardiac disease is now considered a survivable disease, mortality is not an appropriate endpoint for investigations. Because of the extensive follow-up inherent in this population, an opportunity for long-term endpoints exists. Although MODS and critical cardiac disease have been traditionally thought of as an acute problem; the congenital heart disease population allows examination of the chronicity and long-term outcomes of MODS.
Cancer and antineoplastic Therapies
Cancer has long been associated with multiple organ dysfunction (21, 22) . The organ dysfunction may not only be a result of the disease process and its associated comorbidities such as sepsis, but may also emanate from the antineoplastic therapies. As innovative therapies emerge and are implemented for an ever-expanding list of high-risk patients and refractory disease processes, the ability to recognize and address adverse organ dysfunction in a prompt and effective manner will be necessary to optimize treatment outcomes. When organ dysfunction is associated with specific antineoplastic regimens, it is similar to congenital heart surgery with CPB, in that both represent scheduled interventions with a known propensity to incite organ injury. Clinical situations such as these in which the known insult can be anticipated would appear to foster greater opportunity for successful intervention.
Recently, after decades of investigation, effective methods of utilizing immune cells to recognize and eliminate cancer are becoming reality. Most notably, genetic engineering of autologous T-cells with chimeric antigen receptors (CARs) and T-cell receptors has resulted in unprecedented responses in children and adults with relapsed, refractory pre-B-cell acute lymphoblastic leukemia (ALL) (23) (24) (25) , synovial cell sarcoma, or melanoma (26), respectively. However, this transformative therapy has also been reported to be associated with a pathophysiologic process known as the "cytokine release syndrome."
Cytokine release syndrome (CRS) is a constellation of symptoms along a spectrum ranging from mild with only fever to severe with very high fever, rigors, headache, flushing, tachypnea, severe tachycardia, coagulopathy, hypoxia, pulmonary edema, hypotension requiring vasopressors, and/or respiratory failure (27) . Severity of CRS seems to be related to overall tumor burden, and almost all patients who respond have some degree of CRS (23) . Left unchecked, severe CRS will result in multiple organ failure typically beginning with the rapid development of biventricular cardiac dysfunction then failure, acute pulmonary edema resulting in hypoxemic respiratory failure, acute kidney injury at times requiring renal replacement therapy, hepatic dysfunction, and severe coagulopathy. Neurotoxicities observed in CAR therapy for ALL appear to be related to CRS, but often present as an isolated phenomenon outside the context of typical multisystem CRS (23, 25) . Activated CAR T-cells produce massive quantities of inflammatory cytokines such as interferon-γ, tumor necrosis factor-α (TNF-α), and interleukin (IL)-2, which in turn activate other aspects of cellular immunity inducing robust production of IL-6 (27) . IL-6 clearly drives the symptoms noted in CRS. Serum IL-6 levels in responding patients have been measured to be greater than 3,000 pg/mL (normal < 10 pg/mL), and the fever and hemodynamic instability reported in CRS can be reversed within hours of the administration of the anti-IL-6 receptor monoclonal antibody, tocilizumab (23) (24) (25) 27) .
Clinical experience suggests that the timely administration of tocilizumab with or without corticosteroids to the patient with moderate-grade CRS is of paramount importance in preventing severe, life-threatening CRS characterized by multiple organ dysfunction although this has not been confirmed in phase II or III trials. This is one instance where MODS may actually be prevented. However, early recognition and treatment are critical as patients who have already progressed to organ failure are rarely rescued even with anticytokine therapy. In addition, it will be important to assess if such an approach can be successful in other clinical conditions in which cytokine release drives multiple organ dysfunction.
Hematopoietic Cell Transplantation
Hematopoietic cell transplantation (HCT) is another antineoplastic therapy that has emerged over the past 25 years as the only curative therapy for children with a number of malignant, as well as nonmalignant, disorders of the blood and immune systems. In its more traditional mode, HCT recipients are treated with supralethal doses of anticancer therapy (chemo-and/or irradiation therapy) and subsequently "rescued" by the infusion of hematopoietic stem cells. Despite significant advances in critical care and transplantation medicine, optimal outcomes following allogeneic HCT continue to be limited by the occurrence of organ dysfunction as the result of the development of acute graft-versus-host disease (GVHD), acute pulmonary dysfunction, thrombotic microangiopathy, and venoocclusive disease (VOD)/sinusoidal obstruction syndrome (SOS) of the liver.
GVHD describes a disease process wherein immune cells in the donor stem cell "graft" respond to foreign antigens in the "host." Immunologic dysregulation occurring after allogeneic HCT contributes to GVHD. However, donor T-cell activation also enhances the therapeutic potential of HCT through powerful graft versus tumor effects that persist long after the chemo-and irradiation therapy effects have passed. The pathophysiology of acute GVHD is complex (28) (29) (30) . Immune dysregulation can be conceptualized in three distinct phases (29) and involves diffuse damage and activation of host tissues by HCT conditioning regimens (phase 1), the activation of donor T-cells by host antigen-presenting cells (phase 2), and the culmination of target organ damage by soluble and cellular effectors (phase 3). Although components of this paradigm have been challenged and refined (30) , the hypothesis identifies areas where novel agents can be explored. The onset of acute GVHD typically occurs within the first 2 months after allogeneic HCT, and the classic target organs include the gastrointestinal tract, liver, and skin. Historically, the occurrence and severity of GVHD have correlated with the donor type (related vs unrelated) and the degree of antigenic disparity between the donor and host. Advanced (grades 3 to 4) GVHD remains life threatening and often times requires critical care support to manage direct (organ dysfunction) and indirect (opportunistic infection) manifestations of disease.
Pulmonary complications in a variety of forms occur in 25-55% of HCT recipients and can account for approximately 40% of transplant-related mortality. Historically, approximately 50% of cases were determined to be noninfectious in origin, but the judicious use of broad-spectrum antimicrobial prophylaxis in recent years has tipped the balance of pulmonary complications from infectious to noninfectious causes (31) . The idiopathic pneumonia syndrome (IPS) refers to noninfectious lung injury that occurs acutely within the first 120 days following HCT (31) (32) (33) (34) . Diagnostic criteria of IPS include signs and symptoms of pneumonia, nonlobar radiographic infiltrates, abnormal pulmonary function, and the absence of infectious organisms as determined by bronchoalveolar lavage or lung biopsy. IPS has been a frequently fatal complication of HCT, associated with mortality rates in excess of 70% with a median time from diagnosis to death of only 2 weeks (31-34). Potential etiologies for IPS include direct toxic effects of HCT conditioning regimens, occult pulmonary infections, and the release of inflammatory cytokines that have been implicated in other forms of pulmonary injury (31) . Clinically, the diagnosis of IPS has been linked to the development of acute GVHD. Although this association suggests the importance of alloreactivity to lung injury that occurs after HCT, a causal relationship between IPS and GVHD is yet to be firmly established.
Clinical syndromes presenting with microangiopathic hemolytic anemia, with consumptive thrombocytopenia, and often with renal insufficiency and encephalopathy have long been recognized as potentially devastating multisystem complications after HCT (35) . Although several terms have been used in the literature to describe these microangiopathic processes, transplant-associated thrombotic microangiopathy (TA-TMA) is now widely accepted as an umbrella term to cover these disorders (36) .The diagnosis of TA-TMA is based on clinical criteria and the classic presentation, which includes the relatively acute onset of anemia and thrombocytopenia with evidence of RBC fragmentation in the peripheral blood smear (37) . Concomitant acute renal dysfunction, often associated with proteinuria and hypertension, occurs in the majority of patients, and neurologic deficits, including but not restricted to confusion and seizures, are also commonly observed. The onset of TA-TMA usually occurs within the first 100 days after HCT, and the median time of onset ranged from 44 to 67 days in two large retrospective reports (38, 39) . TA-TMA occurs less frequently Pediatric Critical Care Medicine www.pccmjournal.org
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after autologous HCT (up to 2.6%) compared with the allogeneic setting where the occurrence rate is in the 10-15% range and even higher in some recent pediatric reports given the close association of TA-TMA with calcineurin inhibitors, GVHD, and infections (38, 40) . Recognizing the need to standardize definitions for toxicity reporting in multicenter clinical trials and to facilitate future clinical investigative efforts, U.S. and European working groups have recently proposed specific sets of clinical criteria for reporting TA-TMA (39, 41) .
The primary inciting events leading to the development of TA-TMA remain poorly understood, but evidence suggests that damage to the vascular endothelium is central to its pathogenesis and may represent a common thread underlying several of the other posttransplant complications (37) . In this context, TA-TMA is now believed to be a multivisceral disorder and should be included in the differential diagnosis of usual HCT complications (36) . For example, pulmonary TMA presenting as pulmonary hypertension should be considered in patients with respiratory failure (42, 43) . Recent reports have also found that TMA can affect the intestinal tract and present with abdominal pain and bloody diarrhea, thereby imitating enteric GVHD or infectious colitis (44, 45) . The diagnosis of intestinal TMA relies primarily on histopathologic evaluation, demonstrating hyaline thrombi in the capillaries of intestinal biopsies or the presence of thrombonecrotic arteriolar lesions in the intestine on autopsy (44, 45) . Recent reports have revealed that activation and dysregulation of the complement alternative pathway may be a major contributor to endothelial damage incurred during TA-TMA (46, 47) . These findings are significant as they may identify a genetic susceptibility for disease development and ultimately guide the institution of novel treatment strategies to improve outcomes.
Approximately 12-18% of patients with TA-TMA will have severe disease affecting their outcome. Proteinuria and activated terminal complement at TA-TMA diagnosis are very poor prognostic markers, and prompt clinical interventions should be considered (40) . Unfortunately, there is currently no standard treatment for TA-TMA, but there is consensus that rapid withdrawal of potential offending drugs such as calcineurin inhibitors or sirolimus should be the primary intervention. Aggressive management of concurrent GVHD and infections is crucial since these are common causes of mortality in patients with TA-TMA. Although often used, plasma exchange (PE) has demonstrated limited efficacy and has not been endorsed as a standard treatment; response rates are generally less than 50%, and mortality rates among patients treated with PE remain unacceptably high (41) . Early implementation of PE in pediatric patients may rescue some patients with renal failure, but outcomes remain poor (48) . The fact that TA-TMA results from direct injury to endothelial cells and not from circulating antibody may explain the low response rates to PE and supports the use of other agents that inhibit complement (eculizumab) (49) or stabilize vascular endothelial integrity and function (50) to improve outcomes.
VOD/SOS is recognized as another complication associated with high-dose chemotherapy and HCT that may result in multiple organ dysfunction. It results from direct injury to sinusoidal endothelium, hepatocytes, and the central venules in zone 3 of the liver acinus that ultimately progresses to venoocclusion and sinusoidal obstruction (51) (52) (53) (54) . VOD/SOS is characterized clinically by painful hepatomegaly, jaundice, and fluid retention as manifested by weight gain and ascites that typically occurs within 30 days of HCT. The clinical diagnosis of VOD/SOS is based on the classical triad of weight gain, painful hepatomegaly, and jaundice as characterized by the Seattle (51) and Baltimore (55) transplant groups. Making the diagnosis of VOD/SOS can be challenging because the signs and symptoms of this condition often overlap those of other processes (54) . In this context, the time of onset is often useful in narrowing the differential diagnosis. The severity of VOD/SOS ranges from mild to severe depending on the degree of hyperbilirubinemia, the amount of fluid retention, and the pace of disease progression (56) (57) (58) . When associated with MODS, specifically involving pulmonary and renal impairment, VOD/SOS has historically been associated with unacceptably high mortality rates that approach 100% despite advances in mechanical ventilation and continuous renal replacement therapy (54, 58) .
Optimization of care in the immediate post-HCT period and minimization of potential organ dysfunction are essential for successful outcomes as the degree of MODS has clearly been associated with survival in the HCT population (21, 59) . Indeed, the development of novel strategies that reduce transplantrelated toxicity, regulate GVHD, preserve graft versus tumor effects, and facilitate engraftment and long-term immune reconstitution remains the most significant challenge to broadening the scope of allogeneic HCT. The development of novel therapies to treat and prevent acute GVHD, translational research efforts underscoring a critical role for TNF inhibitors in the management of IPS (60, 61) , and the introduction of an endothelial stabilizing agent (defibrotide) for the management of hepatic VOD/ SOS (62, 63) have represented major advances in the field. These breakthroughs in combination with the discovery of biomarkers that may predict the development, severity, and response to therapy of these complications (64) (65) (66) (67) are being considered in the development of rationally designed, translational research trials aimed at identifying patients at risk, limiting the occurrence of MODS, and improving patient outcomes after allogeneic HCT.
CONClUSIONS
In summary, there are a number of medical conditions and therapeutic interventions that are associated with multiple organ dysfunction and the MODS. The intent of this article, as with the accompanying article, is to highlight a handful of those conditions and therapies in an attempt to identify areas of commonality, areas of difference, and opportunities for further study and intervention; it was not to present an exhaustive list of the many etiologies that may result in MODS. It is hoped that by considering this syndrome in relation to a number of disparate conditions, investigators may gain new insight and avenues for study that will advance our understanding of this process from that of a syndrome (i.e., simply a collection of related symptoms) to a well-defined clinical entity with established pathophysiologic causes, genetic predispositions, and targeted therapies.
